Balancing innovation, access, and market competition in a post-pandemic world as the USPTO reviews the link between drug pricing and exclusivity, other regions (including the European Medicines Agency (EMA), China's NMPA, and India's IPO)are also scrutinizing their pharmaceutical patent frameworks. This session will explore the global trends in drug pricing regulation, compulsory licensing, and IP reform, highlighting how different jurisdictions balance innovation incentives with public health priorities. Experts will discuss strategies for multinational pharmaceutical companies navigating evolving IP and pricing policies across key markets